{
    "id": "1d79bd78-5405-4df3-b4d9-4e95abcf540b",
    "indications": "rinvoq/rinvoq lq janus kinase ( jak ) inhibitor . rinvoq indicated treatment adults moderately severely active rheumatoid arthritis inadequate response intolerance one tnf blockers . ( 1.1 ) limitations rinvoq recommended combination jak inhibitors , biologic dmards , potent immunosuppressants azathioprine cyclosporine . ( 1.1 ) rinvoq/rinvoq lq indicated treatment adults pediatric patients 2 years age older active psoriatic arthritis inadequate response intolerance one tnf blockers . ( 1.2 ) limitation rinvoq/rinvoq lq recommended combination jak inhibitors , biologic dmards , potent immunosuppressants azathioprine cyclosporine . ( 1.2 ) rinvoq indicated treatment adults pediatric patients 12 years age older refractory , moderate severe atopic dermatitis whose disease adequately controlled systemic products , including biologics , therapies inadvisable . ( 1.3 ) limitations rinvoq recommended combination jak inhibitors , biologic immunomodulators , immunosuppressants . ( 1.3 ) rinvoq indicated treatment adults moderately severely active ulcerative colitis inadequate response intolerance one tnf blockers . ( 1.4 ) limitations rinvoq recommended combination jak inhibitors , biological therapies ulcerative colitis , potent immunosuppressants azathioprine cyclosporine . ( 1.4 ) rinvoq indicated treatment adults moderately severely active crohn ’ disease inadequate response intolerance one tnf blockers . ( 1.5 ) limitations rinvoq recommended combination jak inhibitors , biological therapies crohn ’ disease , potent immunosuppressants azathioprine cyclosporine . ( 1.5 ) rinvoq indicated treatment adults active ankylosing spondylitis inadequate response intolerance one tnf blockers . ( 1.6 ) limitations rinvoq recommended combination jak inhibitors , biologic dmards , potent immunosuppressants azathioprine cyclosporine . ( 1.6 ) rinvoq indicated treatment adults active non-radiographic axial spondyloarthritis objective signs inflammation inadequate response intolerance tnf blocker therapy . ( 1.7 ) limitations rinvoq recommended combination jak inhibitors , biologic dmards , potent immunosuppressants azathioprine cyclosporine . ( 1.7 ) rinvoq/rinvoq lq indicated treatment patients 2 years age older active polyarticular juvenile idiopathic arthritis inadequate response intolerance one tnf blockers . ( 1.8 ) limitations rinvoq/rinvoq lq recommended combination jak inhibitors , biologic dmards , potent immunosuppressants azathioprine cyclosporine . ( 1.8 ) rinvoq indicated treatment adults giant cell arteritis ( 1.9 ) limitations rinvoq recommended combination jak inhibitors , biologic dmards , potent immunosuppressants azathioprine cyclosporine . ( 1.9 )",
    "contraindications": "rinvoq lq oral solution substitutable rinvoq extended-release tablets ( 2.2 , 2.10 ) . changes rinvoq lq oral solution rinvoq extended-release tablets made healthcare provider . prior treatment update immunizations consider evaluating active latent tuberculosis , viral hepatitis , hepatic function , pregnancy status ( 2.1 ) avoid initiation interrupt rinvoq/rinvoq lq absolute lymphocyte count less 500 cells/mm 3 , absolute neutrophil count less 1000 cells/mm 3 , hemoglobin level less 8 g/dl . ( 2.1 , 2.14 ) rheumatoid arthritis , ankylosing spondylitis , non-radiographic axial spondyloarthritis adults : recommended rinvoq 15 mg daily . ( 2.3 , 2.8 , 2.9 ) psoriatic arthritis pediatric patients 2 less 18 years age weighing least 10 kg : recommended based body weight ( 2.4 ) adults : recommended rinvoq 15 mg daily . ( 2.4 ) atopic dermatitis pediatric patients 12 years age older weighing least 40 kg adults less 65 years age : initiate treatment rinvoq 15 mg orally daily . adequate response achieved , consider increasing 30 mg orally daily . ( 2.5 ) adults 65 years age older : recommended rinvoq 15 mg daily . ( 2.5 ) severe renal impairment : recommended rinvoq 15 mg daily . ( 2.12 ) ulcerative colitis adults : recommended induction rinvoq 45 mg daily 8 weeks . recommended maintenance rinvoq 15 mg daily . maintenance 30 mg daily may considered patients refractory , severe , extensive disease . discontinue rinvoq adequate therapeutic response achieved 30 mg . lowest effective needed maintain response . ( 2.6 ) full prescribing information recommended patients renal hepatic impairment modification due . ( 2.12 , 2.13 ) crohn ’ isease adults : recommended induction rinvoq 45 mg daily 12 weeks . recommended maintenance rinvoq 15 mg daily . maintenance 30 mg daily may considered patients refractory , severe , extensive disease . discontinue rinvoq adequate therapeutic response achieved 30 mg . lowest effective needed maintain response . ( 2.7 ) full prescribing information recommended patients renal hepatic impairment modification due . ( 2.12 , 2.13 ) polyarticular juvenile idiopathic arthritis recommended based body weight ( 2.10 ) giant cell arteritis recommended rinvoq 15 mg daily combination tapering course corticosteroids . rinvoq 15 mg daily used monotherapy following discontinuation corticosteroids ( 2.11 )",
    "warningsAndPrecautions": "supplied rinvoq extended-release tablets supplied : 15 mg : purple , biconvex oblong , dimensions 14 x 8 mm , debossed ‘ a15 ’ one side . 30 tablets bottle ; ndc : 0074-2306-30 30 mg : red , biconvex oblong , dimensions 14 x 8 mm , debossed ‘ a30 ’ one side . 30 tablets bottle ; ndc : 0074-2310-30 45 mg : yellow mottled yellow , biconvex oblong , dimensions 14 x 8 mm , debossed ‘ a45 ’ one side . 28 tablets bottle ; ndc : 0074-1043-28 rinvoq lq oral solution supplied : 1 mg/ml oral solution hdpe bottles child-resistant cap . bottle contains labeled volume 180 ml clear , colorless light yellow solution . bottle packaged carton one press-in bottle adapter one 10 ml oral dosing syringe ; ndc : 0074-2320-01 storage handling rinvoq extended-release tablets store 2˚c 25˚c ( 36˚f 77˚f ) . store original bottle order protect moisture . rinvoq lq oral solution store 2°c 30°c ( 36°f 86°f ) . discard remaining oral solution 60 days opening bottle .",
    "adverseReactions": "rinvoq/rinvoq lq contraindicated patients known hypersensitivity upadacitinib excipients [ ( 5.6 ) ] .",
    "ingredients": [
        {
            "name": "upadacitinib",
            "code": "4RA0KN46E0"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "UPADACITINIB",
            "code": "4RA0KN46E0"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        }
    ],
    "organization": "AbbVie Inc.",
    "name": "Rinvoq",
    "effectiveTime": "20250428",
    "indications_original": "RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent  immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )",
    "contraindications_original": "RINVOQ LQ oral solution is not substitutable with RINVOQ extended-release tablets ( 2.2 , 2.10 ). Changes between RINVOQ LQ oral solution and RINVOQ extended-release tablets should be made by the healthcare provider. Prior to treatment update immunizations and consider evaluating for active and latent tuberculosis, viral hepatitis, hepatic function, and pregnancy status ( 2.1 ) Avoid initiation or interrupt RINVOQ/RINVOQ LQ if absolute lymphocyte count is less than 500 cells/mm 3 , absolute neutrophil count is less than 1000 cells/mm 3 , or hemoglobin level is less than 8 g/dL. ( 2.1 , 2.14 ) Rheumatoid Arthritis , Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis Adults: The recommended dosage of RINVOQ is 15 mg once daily. ( 2.3 , 2.8 , 2.9 ) Psoriatic Arthritis Pediatric Patients 2 to less than 18 Years of Age Weighing at Least 10 kg: The recommended dosage is based on body weight ( 2.4 ) Adults: The recommended dosage of RINVOQ is 15 mg once daily. ( 2.4 ) Atopic Dermatitis Pediatric Patients 12 Years of Age and Older Weighing at Least 40 kg and Adults Less Than 65 Years of Age : Initiate treatment with RINVOQ 15 mg orally once daily. If an adequate response is not achieved, consider increasing the dosage to 30 mg orally once daily. ( 2.5 ) Adults 65 Years of Age and Older : Recommended dosage of RINVOQ is 15 mg once daily. ( 2.5 ) Severe Renal Impairment : Recommended dosage of RINVOQ is 15 mg once daily. ( 2.12 ) Ulcerative Colitis Adults: The recommended induction dosage of RINVOQ is 45 mg once daily for 8 weeks. The recommended maintenance dosage of RINVOQ is 15 mg once daily. A maintenance dosage of 30 mg once daily may be considered for patients with refractory, severe, or extensive disease. Discontinue RINVOQ if adequate therapeutic response is not achieved with the 30 mg dosage. Use the lowest effective dosage needed to maintain response. ( 2.6 ) See the Full Prescribing Information for the recommended dosage in patients with renal or hepatic impairment and for dosage modification due to drug interactions. ( 2.12 , 2.13 ) Crohn’s D isease Adults: The recommended induction dosage of RINVOQ is 45 mg once daily for 12 weeks. The recommended maintenance dosage of RINVOQ is 15 mg once daily. A maintenance dosage of 30 mg once daily may be considered for patients with refractory, severe, or extensive disease. Discontinue RINVOQ if an adequate therapeutic response is not achieved with the 30 mg dosage. Use the lowest effective dosage needed to maintain response. ( 2.7 ) See the Full Prescribing Information for the recommended dosage in patients with renal or hepatic impairment and for dosage modification due to drug interactions. ( 2.12 , 2.13 ) Polyarticular Juvenile Idiopathic Arthritis The recommended dosage is based on body weight ( 2.10 ) Giant Cell Arteritis The recommended dosage of RINVOQ is 15 mg once daily in combination with a tapering course of corticosteroids. RINVOQ 15 mg once daily can be used as monotherapy following discontinuation of corticosteroids ( 2.11 )",
    "warningsAndPrecautions_original": "How Supplied\n                  \n                  RINVOQ extended-release tablets are supplied as:\n                  \n                     15 mg: purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. 30 tablets in a bottle; NDC: 0074-2306-30 \n                     \n                     30 mg: red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. 30 tablets in a bottle; NDC: 0074-2310-30\n                     \n                     45 mg: yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. 28 tablets in a bottle; NDC: 0074-1043-28 \n                  \n                  RINVOQ LQ oral solution is supplied as:\n                  \n                     A 1 mg/mL oral solution in HDPE bottles with a child-resistant cap. Each bottle contains a labeled volume of 180 mL of clear, colorless to light yellow solution. The bottle is packaged in a carton with one press-in bottle adapter and one 10 mL oral dosing syringe; NDC: 0074-2320-01\n                  \n                  \n                     Storage and Handling\n                  \n                  RINVOQ extended-release tablets\n                  \n                     Store at 2˚C to 25˚C (36˚F to 77˚F). \n                     \n                     Store in the original bottle in order to protect from moisture. \n                  \n                  RINVOQ LQ oral solution\n                  \n                     Store between 2°C to 30°C (36°F to 86°F).\n                     \n                     Discard remaining oral solution 60 days after opening the bottle.",
    "adverseReactions_original": "RINVOQ/RINVOQ LQ is contraindicated in patients with known hypersensitivity to upadacitinib or any of its excipients [see Warnings and Precautions (\n                     \n                        5.6\n                     \n                     )]."
}